Clinical trial
Cabergoline Reduces OHSS
NCT00440258 · Instituto Valenciano de Infertilidad, IVI VALENCIA, Other · Completed
Key facts
| NCT number | NCT00440258 |
|---|---|
| Title | Cabergoline Reduces OHSS |
| Official title | Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction. |
| Lead sponsor | Instituto Valenciano de Infertilidad, IVI VALENCIA, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Hyperstimulation Syndrome |
| Intervention type | Drug, Procedure |
| Interventions | Cabergoline, MR, Ultrasound, Blood Analysis |
| Enrollment | 60 |
| Start date | Apr 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | Feb 26, 2007 |
| Last update posted | Feb 27, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: